Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 6/20 | 0.36 |
| ▸ | MAPK9 | P45984 | 6/20 | 0.36 |
| ▸ | JUN | P05412 | 2/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 6/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | PIKFYVE | Q9Y2I7 | 1/20 | 0.35 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 3/20 | 0.35 |
| ▸ | CKS1B | P61024 | 2/20 | 0.35 |
| ▸ | SKP1 | P63208 | 2/20 | 0.35 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.35 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
| ▸ | ACACA | Q13085 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5913810 | 0.80 | MAPK8 (0.48) | USP30MAPK8MAPK9JUNMAPK10 | |
| SCHEMBL5913964 | 0.78 | MAPK8 (0.44) | MAPK8MAPK9JUNMAPK10MAPK14 | |
| SCHEMBL5914134 | 0.77 | MAPK8 (0.44) | USP30MAPK8MAPK9JUNMAPK10 | |
| SCHEMBL5266019 | 0.74 | MAPK8 (0.54) | MAPK8MAPK9MAPK10MAPK14CKS1B | |
| SCHEMBL5914206 | 0.74 | MAPK8 (0.41) | MAPK8MAPK9JUNMAPK10MAPK14 | |
| SCHEMBL5914214 | 0.74 | MAPK8 (0.41) | MAPK8MAPK9JUNMAPK10MAPK14 | |
| SCHEMBL5264843 | 0.72 | MAPK14 (0.41) | MAPK14CKS1BSKP1SKP2 | |
| SCHEMBL5914425 | 0.72 | IKBKB (0.47) | MAPK8MAPK14PTK2CDK2 | |
| SCHEMBL5913811 | 0.70 | MAPK8 (0.42) | MAPK8MAPK9MAPK10MAPK14CDK2 | |
| SCHEMBL5913834 | 0.70 | MAPK8 (0.42) | MAPK8MAPK9MAPK10MAPK14CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060069110-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069110-A1 | Substituted heterocyclic compounds and methods of use | MAPT, MYLK2, IAPP | USP30 3267/4885MAPK8 1760/4885MAPK9 2753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.